Please wait





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  The number represents shares of common stock, $0.0001 par value ("Common Stock") of Terns Pharmaceuticals, Inc. (the "Issuer") held of record by Vivo Capital Fund VIII, L.P. as of January 31, 2026. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. The percentage is based on 106,198,970 shares of Common Stock of the Issuer outstanding as of December 11, 2025, as disclosed in the prospectus supplement filed by the Issuer on December 11, 2025 with the Securities and Exchange Commission ("SEC") pursuant to Rule 424(b)(5), which forms part of the Issuer's Registration Statement on Form S-3 (File No. 333-292016).


SCHEDULE 13G




Comment for Type of Reporting Person:  The number represents shares of Common Stock of the Issuer held of record by Vivo Capital Surplus Fund VIII, L.P. as of January 31, 2026. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. The percentage is based on 106,198,970 shares of Common Stock of the Issuer outstanding as of December 11, 2025, as disclosed in the prospectus supplement filed by the Issuer on December 11, 2025, with the SEC pursuant to Rule 424(b)(5), which forms part of the Issuer's Registration Statement on Form S-3 (File No. 333-292016).


SCHEDULE 13G




Comment for Type of Reporting Person:  The number represents shares of Common Stock of the Issuer held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. as of January 31, 2026. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. The percentage is based on 106,198,970 shares of Common Stock of the Issuer outstanding as of December 11, 2025, as disclosed in the prospectus supplement filed by the Issuer on December 11, 2025, with the SEC pursuant to Rule 424(b)(5), which forms part of the Issuer's Registration Statement on Form S-3 (File No. 333-292016).


SCHEDULE 13G




Comment for Type of Reporting Person:  The number represents shares of Common Stock held of record by Vivo Opportunity Fund Holdings, L.P. as of January 31, 2026. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The percentage is based on 106,198,970 shares of Common Stock of the Issuer outstanding as of December 11, 2025, as disclosed in the prospectus supplement filed by the Issuer on December 11, 2025, with the SEC pursuant to Rule 424(b)(5), which forms part of the Issuer's Registration Statement on Form S-3 (File No. 333-292016).


SCHEDULE 13G




Comment for Type of Reporting Person:  The number represents shares of Common Stock held of record by Vivo Opportunity Fund Holdings, L.P. as of January 31, 2026. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The percentage is based on 106,198,970 shares of Common Stock of the Issuer outstanding as of December 11, 2025, as disclosed in the prospectus supplement filed by the Issuer on December 11, 2025, with the SEC pursuant to Rule 424(b)(5), which forms part of the Issuer's Registration Statement on Form S-3 (File No. 333-292016).


SCHEDULE 13G




Comment for Type of Reporting Person:  The number represents shares of Common Stock held of record by Vivo Opportunity Cayman Fund, L.P. as of January 31, 2026. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. The percentage is based on 106,198,970 shares of Common Stock of the Issuer outstanding as of December 11, 2025, as disclosed in the prospectus supplement filed by the Issuer on December 11, 2025, with the SEC pursuant to Rule 424(b)(5), which forms part of the Issuer's Registration Statement on Form S-3 (File No. 333-292016).


SCHEDULE 13G




Comment for Type of Reporting Person:  The number represents shares of Common Stock held of record by Vivo Opportunity Cayman Fund, L.P. as of January 31, 2026. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. The percentage is based on 106,198,970 shares of Common Stock of the Issuer outstanding as of December 11, 2025, as disclosed in the prospectus supplement filed by the Issuer on December 11, 2025, with the SEC pursuant to Rule 424(b)(5), which forms part of the Issuer's Registration Statement on Form S-3 (File No. 333-292016).


SCHEDULE 13G



 
Vivo Capital Fund VIII, L.P.
 
Signature:/s/ Frank Kung
Name/Title:Frank Kung/Managing Member of Vivo Capital VIII, LLC, General Partner
Date:02/13/2026
 
Vivo Capital Surplus Fund VIII, L.P.
 
Signature:/s/ Frank Kung
Name/Title:Frank Kung/Managing Member of Vivo Capital VIII, LLC, General Partner
Date:02/13/2026
 
Vivo Capital VIII, LLC
 
Signature:/s/ Frank Kung
Name/Title:Frank Kung/Managing Member
Date:02/13/2026
 
Vivo Opportunity Fund Holdings, L.P.
 
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member of Vivo Opportunity, LLC, General Partner
Date:02/13/2026
 
Vivo Opportunity, LLC
 
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member
Date:02/13/2026
 
Vivo Opportunity Cayman Fund, L.P.
 
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member of Vivo Opportunity Cayman, LLC, General Partner
Date:02/13/2026
 
Vivo Opportunity Cayman, LLC
 
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member
Date:02/13/2026